Finance

Lists
G1SK34:BVMF
Gsk Plc Bdr
R$ ५०.५०
०.००%
(०.००) 1D
अक्टोबर १६, १६:५६:०० GMT-३  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for G1SK34...
Open
R$ ५०.१०
High
R$ ५०.७५
Low
R$ ५०.१०
Mkt. cap
१.०० खरब
Avg. vol.
२१४.००
Volume
१६५.००
52-wk high
R$ ६३.२४
52-wk low
R$ ४६.१५
Shares outstanding
४.३२ अरब
No. of employees
६७ हजार
Open
R$ ५०.१०
High
R$ ५०.७५
Low
R$ ५०.१०
Mkt. cap
१.०० खरब
Avg. vol.
२१४.००
Volume
१६५.००
52-wk high
R$ ६३.२४
52-wk low
R$ ४६.१५
Shares outstanding
४.३२ अरब
No. of employees
६७ हजार
News stories
From web sources and news partners
The Globe and Mail
The Globe and Mail
·
१२ घण्टा पहिले
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Traders Union
Traders Union
·
१६ घण्टा पहिले
GSK shares technical analysis: Overbought conditions highlight reversal setup
JournalArta
JournalArta
·
२३ घण्टा पहिले
GSK Stock Gains 2.89% on Thursday: Full Details
Yahoo Finance
Yahoo Finance
·
१ दिन पहिले
Better Dividend Stock: Pfizer vs. GSK
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About Gsk Plc Bdr
CEOEmma Walmsley | Emma Walmsley
Employees६६.८ हजार
Founded२००० डिसेम्बर २७
Headquarters-
Sector-
Websitegsk.com
Next call ११ दिनमा
अक्टोबर २८, बुध, १४:००
Fiscal period
Q3 2026
- / £ ०.५०
Revenue / Est. (GBP)
- / ८.८१ अरब
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
८.५५ अरब
८.६२ अरब
७.६३ अरब
८.४१ अरब
Cost of goods sold
२.२४ अरब
२.६२ अरब
१.८७ अरब
२.०७ अरब
Cost of revenue
२.२४ अरब
२.६२ अरब
१.८७ अरब
२.०७ अरब
Research and development expenses
१.५८ अरब
२.१४ अरब
१.५२ अरब
१.७५ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.१६ अरब
२.६७ अरब
२.०८ अरब
२.१९ अरब
Operating expense
३.२३ अरब
४.३७ अरब
२.९९ अरब
३.७४ अरब
Total operating expenses
५.४६ अरब
६.९९ अरब
४.८६ अरब
५.८१ अरब
Operating income
३.०८ अरब
१.६३ अरब
२.७७ अरब
२.६० अरब
Other non operating income
-
-२.१० करोड
-
-
EBT including unusual items
२.४६ अरब
९५.०० करोड
२.१४ अरब
३५.४० करोड
EBT excluding unusual items
२.९४ अरब
१.४८ अरब
२.६२ अरब
२.४८ अरब
Income tax expense
३१.२० करोड
२२.३० करोड
३०.५० करोड
-१९.९० करोड
Effective tax rate
१२.७०%
२३.४७%
१४.२३%
-५६.२१%
Other operating expenses
-५१.१० करोड
-४३.४० करोड
-६१.५० करोड
-२०.४० करोड
Net income
२.०१ अरब
६३.६० करोड
१.७४ अरब
४३.५० करोड
Net profit margin
२३.५५%
७.३८%
२२.७७%
५.१७%
Earnings per share
०.५५
-
-
-
Interest and investment income
२.६० करोड
१.७० करोड
२.२० करोड
५.८० करोड
Interest expense
-१६.७० करोड
-१४.५० करोड
-१६.७० करोड
-१८.२० करोड
Net interest expenses
-१४.१० करोड
-१२.८० करोड
-१४.५० करोड
-१२.४० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
३.८२ अरब
२.६९ अरब
३.२३ अरब
२.८२ अरब
Gain or loss from assets sale
-
-४.०० करोड
-
-
AI content may include mistakes. Learn more
Google एपहरू